{"filing":{"accession_number":"0001213900-26-069911","cik":"0001739174","ticker":"PHGE","company_name":"BiomX Inc.","form":"8-K","filing_date":"2026-06-18","report_date":null,"primary_document":"ea0295251-8k_biomx.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1739174/000121390026069911/ea0295251-8k_biomx.htm"},"events":[{"id":11734,"run_id":10315,"accession_number":"0001213900-26-069911","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"summary":"BiomX disclosed a strategic transition to a defense and security technology holding company and posted an updated investor presentation reflecting this repositioning. While Item 7.01 (Regulation FD Disclosure) is typically used for routine informational updates, the substance here—a completed \"fundamental strategic transition\" away from legacy clinical-stage biotech activities—is material to investors' understanding of the company's business model, portfolio, and strategy. The press release and presentation emphasize real deployments, customer relationships (Elbit Systems, Rafael), and a new operating framework (Detection-Analysis-Response), which would affect a reasonable investor's assessment. However, this does not fit neatly into the specific event-type taxonomy (not M\u0026A, not an executive change, not a restatement or impairment), so \"other_material\" is most appropriate.","company_name":"BiomX Inc.","ticker":"PHGE","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8396,"accession_number":"0001213900-26-069911","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"BiomX disclosed a strategic transition to a defense and security technology holding company and posted an updated investor presentation reflecting this repositioning. While Item 7.01 (Regulation FD Disclosure) is typically used for routine informational updates, the substance here—a completed \"fundamental strategic transition\" away from legacy clinical-stage biotech activities—is material to investors' understanding of the company's business model, portfolio, and strategy. The press release and presentation emphasize real deployments, customer relationships (Elbit Systems, Rafael), and a new operating framework (Detection-Analysis-Response), which would affect a reasonable investor's assessment. However, this does not fit neatly into the specific event-type taxonomy (not M\u0026A, not an executive change, not a restatement or impairment), so \"other_material\" is most appropriate.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T13:22:09.900190+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8396,"accession_number":"0001213900-26-069911","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"BiomX disclosed a strategic transition to a defense and security technology holding company and posted an updated investor presentation reflecting this repositioning. While Item 7.01 (Regulation FD Disclosure) is typically used for routine informational updates, the substance here—a completed \"fundamental strategic transition\" away from legacy clinical-stage biotech activities—is material to investors' understanding of the company's business model, portfolio, and strategy. The press release and presentation emphasize real deployments, customer relationships (Elbit Systems, Rafael), and a new operating framework (Detection-Analysis-Response), which would affect a reasonable investor's assessment. However, this does not fit neatly into the specific event-type taxonomy (not M\u0026A, not an executive change, not a restatement or impairment), so \"other_material\" is most appropriate.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T13:22:09.900190+00:00","company_name":"BiomX Inc.","ticker":"PHGE","filing_date":"2026-06-18"}]}